329 related articles for article (PubMed ID: 23374145)
1. Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomide.
Henry JY; Labarthe MC; Meyer B; Dasgupta P; Dalgleish AG; Galustian C
Immunology; 2013 Jul; 139(3):377-85. PubMed ID: 23374145
[TBL] [Abstract][Full Text] [Related]
2. Expansion of polyfunctional HIV-specific T cells upon stimulation with mRNA electroporated dendritic cells in the presence of immunomodulatory drugs.
De Keersmaecker B; Allard SD; Lacor P; Schots R; Thielemans K; Aerts JL
J Virol; 2012 Sep; 86(17):9351-60. PubMed ID: 22718823
[TBL] [Abstract][Full Text] [Related]
3. Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model.
Vo MC; Yang S; Jung SH; Chu TH; Lee HJ; Lakshmi TJ; Park HS; Kim HJ; Lee JJ
Front Immunol; 2018; 9():1798. PubMed ID: 30123221
[TBL] [Abstract][Full Text] [Related]
4. Tumour-associated glycan modifications of antigen enhance MGL2 dependent uptake and MHC class I restricted CD8 T cell responses.
Singh SK; Streng-Ouwehand I; Litjens M; Kalay H; Saeland E; van Kooyk Y
Int J Cancer; 2011 Mar; 128(6):1371-83. PubMed ID: 20473945
[TBL] [Abstract][Full Text] [Related]
5. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.
Singh SK; Stephani J; Schaefer M; Kalay H; García-Vallejo JJ; den Haan J; Saeland E; Sparwasser T; van Kooyk Y
Mol Immunol; 2009 Dec; 47(2-3):164-74. PubMed ID: 19818504
[TBL] [Abstract][Full Text] [Related]
6. TLR7 triggering with polyuridylic acid promotes cross-presentation in CD8α+ conventional dendritic cells by enhancing antigen preservation and MHC class I antigen permanence on the dendritic cell surface.
Crespo MI; Zacca ER; Núñez NG; Ranocchia RP; Maccioni M; Maletto BA; Pistoresi-Palencia MC; Morón G
J Immunol; 2013 Feb; 190(3):948-60. PubMed ID: 23284054
[TBL] [Abstract][Full Text] [Related]
7. Hypofractionated radiotherapy combined with lenalidomide improves systemic antitumor activity in mouse solid tumor models.
Onyshchenko K; Luo R; Rao X; Zhang X; Gaedicke S; Grosu AL; Firat E; Niedermann G
Theranostics; 2024; 14(6):2573-2588. PubMed ID: 38646638
[No Abstract] [Full Text] [Related]
8. A marked reduction in priming of cytotoxic CD8+ T cells mediated by stress-induced glucocorticoids involves multiple deficiencies in cross-presentation by dendritic cells.
Hunzeker JT; Elftman MD; Mellinger JC; Princiotta MF; Bonneau RH; Truckenmiller ME; Norbury CC
J Immunol; 2011 Jan; 186(1):183-94. PubMed ID: 21098225
[TBL] [Abstract][Full Text] [Related]
9. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses.
Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA
Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391
[TBL] [Abstract][Full Text] [Related]
10. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.
Galustian C; Meyer B; Labarthe MC; Dredge K; Klaschka D; Henry J; Todryk S; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB; Dalgleish AG
Cancer Immunol Immunother; 2009 Jul; 58(7):1033-45. PubMed ID: 19009291
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cell maturation enhances CD8+ T-cell responses to exogenous antigen via a proteasome-independent mechanism of major histocompatibility complex class I loading.
Robson NC; Beacock-Sharp H; Donachie AM; Mowat AM
Immunology; 2003 Jul; 109(3):374-83. PubMed ID: 12807483
[TBL] [Abstract][Full Text] [Related]
12. Active dissemination of cellular antigens by DCs facilitates CD8
Gurevich I; Feferman T; Milo I; Tal O; Golani O; Drexler I; Shakhar G
Eur J Immunol; 2017 Oct; 47(10):1802-1818. PubMed ID: 28872666
[TBL] [Abstract][Full Text] [Related]
13. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation.
De Keersmaecker B; Fostier K; Corthals J; Wilgenhof S; Heirman C; Aerts JL; Thielemans K; Schots R
Cancer Immunol Immunother; 2014 Oct; 63(10):1023-36. PubMed ID: 24947180
[TBL] [Abstract][Full Text] [Related]
15. Influenza A infection enhances cross-priming of CD8+ T cells to cell-associated antigens in a TLR7- and type I IFN-dependent fashion.
Wei J; Waithman J; Lata R; Mifsud NA; Cebon J; Kay T; Smyth MJ; Sadler AJ; Chen W
J Immunol; 2010 Nov; 185(10):6013-22. PubMed ID: 20956347
[TBL] [Abstract][Full Text] [Related]
16. Stroma-dependent development of two dendritic-like cell types with distinct antigen presenting capability.
Periasamy P; O'Neill HC
Exp Hematol; 2013 Mar; 41(3):281-92. PubMed ID: 23178375
[TBL] [Abstract][Full Text] [Related]
17. Induction of MHC class I presentation of exogenous antigen by dendritic cells is controlled by CD4+ T cells engaging class II molecules in cholesterol-rich domains.
Machy P; Serre K; Baillet M; Leserman L
J Immunol; 2002 Feb; 168(3):1172-80. PubMed ID: 11801652
[TBL] [Abstract][Full Text] [Related]
18. Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR.
Klechevsky E; Flamar AL; Cao Y; Blanck JP; Liu M; O'Bar A; Agouna-Deciat O; Klucar P; Thompson-Snipes L; Zurawski S; Reiter Y; Palucka AK; Zurawski G; Banchereau J
Blood; 2010 Sep; 116(10):1685-97. PubMed ID: 20530286
[TBL] [Abstract][Full Text] [Related]
19. Anti-inflammatory modulation of human myeloid-derived dendritic cell subsets by lenalidomide.
Yamamoto K; Kitawaki T; Sugimoto N; Fujita H; Kawase Y; Takaori-Kondo A; Kadowaki N
Immunol Lett; 2019 Jul; 211():41-48. PubMed ID: 31141702
[TBL] [Abstract][Full Text] [Related]
20. Plasmacytoid dendritic cells cross-prime naive CD8 T cells by transferring antigen to conventional dendritic cells through exosomes.
Fu C; Peng P; Loschko J; Feng L; Pham P; Cui W; Lee KP; Krug AB; Jiang A
Proc Natl Acad Sci U S A; 2020 Sep; 117(38):23730-23741. PubMed ID: 32879009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]